<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of lung infection with &lt;i&gt;Mycobacterium kansasii &lt;/i&gt;and other less common nontuberculous mycobacteria in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of lung infection with <i>Mycobacterium kansasii </i>and other less common nontuberculous mycobacteria in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of lung infection with <i>Mycobacterium kansasii </i>and other less common nontuberculous mycobacteria in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles L Daley, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shannon Kasperbauer, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">C Fordham von Reyn, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kevin L Winthrop, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allyson Bloom, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 10, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3671275250"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Treatment of nontuberculous mycobacterial (NTM) infection of the lung is dependent upon a number of factors, including the species of the infecting organism. Depending on the geographic area, the most common slow growing NTM to cause lung disease are <em>Mycobacterium avium</em> complex (MAC), <em>Mycobacterium kansasii</em>, <em>Mycobacterium malmoense, and Mycobacterium xenopi</em> [<a href="#rid1">1-4</a>].</p><p>The treatment of lung infections due to <em>M. kansasii</em> and other non-MAC slow growing nontuberculous mycobacteria will be reviewed here. Management of pulmonary infections due to MAC and to rapidly growing mycobacterium (<em>Mycobacterium abscessus</em>, <em>Mycobacterium fortuitum</em> complex, and <em>Mycobacterium chelonae</em>)<em> </em>are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5341.html" rel="external">"Treatment of <i>Mycobacterium avium </i>complex pulmonary infection in adults"</a> and  <a class="medical medical_review" href="/z/d/html/5347.html" rel="external">"Rapidly growing mycobacterial infections: Mycobacteria abscessus, chelonae, and fortuitum"</a>.)</p><p>The epidemiology, microbiology, clinical manifestations, and diagnosis of NTM infection are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5342.html" rel="external">"Overview of nontuberculous mycobacterial infections"</a> and  <a class="medical medical_review" href="/z/d/html/5344.html" rel="external">"Epidemiology of nontuberculous mycobacterial infections"</a> and  <a class="medical medical_review" href="/z/d/html/5346.html" rel="external">"Diagnosis of nontuberculous mycobacterial infections of the lungs"</a>.)</p><p class="headingAnchor" id="H398263296"><span class="h1">M. KANSASII</span><span class="headingEndMark"> — </span><em>M. kansasii</em> was first described by Buhler and Pollack in 1953 as a cause of progressive lung disease [<a href="#rid5">5</a>]. In the United States, <em>M. kansasii</em> is the second most common slow growing nontuberculous mycobacterial (NTM) cause of pulmonary disease after MAC. </p><p class="headingAnchor" id="H1590124003"><span class="h2">Rationale for treatment</span><span class="headingEndMark"> — </span>Antimycobacterial treatment is indicated for most patients diagnosed with <em>M. kansasii </em>lung disease because untreated <em>M. kansasii</em> usually leads to chronic progressive lung disease [<a href="#rid6">6</a>]. Furthermore, outcomes are generally good with treatment of <em>M. kansasii</em>, with rare treatment failures and uncommon relapse. Thus, the benefits of treatment outweigh potential risks in most individuals.</p><p class="headingAnchor" id="H393947503"><span class="h2">Susceptibility testing</span><span class="headingEndMark"> — </span><em>M. kansasii</em> is a yellow pigmented mycobacterium that is typically inhibited by <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">rifabutin</a>, <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a>, <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">ethambutol</a>, <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">ethionamide</a>, <a class="drug drug_general" data-topicid="9309" href="/z/d/drug information/9309.html" rel="external">cycloserine</a>, sulfamethoxazole, <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">clofazimine</a>, <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a>, aminoglycosides, macrolides, and later generation fluoroquinolones [<a href="#rid7">7-12</a>]. We routinely have <em>M. kansasii</em> isolates tested for susceptibility to rifampin (which also corresponds to susceptibility to rifabutin) and macrolides. If rifampin resistance is detected, susceptibility testing of other potential agents (isoniazid, ethambutol, rifabutin, aminoglycosides, sulfonamides, and <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">moxifloxacin</a>) should be performed.</p><p>Resistance to <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> has been described in patients who had prior rifampin exposure, particularly HIV-infected individuals [<a href="#rid13">13</a>], and has been associated with treatment failure. Rifampin resistance has also been associated with resistance to other agents, including <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a> and <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">ethambutol</a> [<a href="#rid7">7</a>]. Isoniazid is generally less active against <em>M. kansasii</em> than against <em>Mycobacterium</em> <em>tuberculosis</em> (ie, minimum inhibitory concentration (MIC) to isoniazid is usually higher for <em>M. kansasii</em>) [<a href="#rid13">13</a>]; however, <em>M. kansasii</em> is usually susceptible to the serum levels of isoniazid achieved with typical dosing, and reported low level resistance to isoniazid (eg, at 0.2 or 1 mcg/mL) is not associated with clinical failure with isoniazid if rifampin is also used in the regimen [<a href="#rid2">2</a>]. </p><p class="headingAnchor" id="H444596254"><span class="h2">Regimen selection</span></p><p class="headingAnchor" id="H1551413932"><span class="h3">Drug-susceptible isolates</span><span class="headingEndMark"> — </span>For most patients with <em>M. kansasii</em>, we suggest treatment with one of the following combination regimens: </p><p class="bulletIndent1"><span class="glyph">●</span>One of the following daily dosed regimens:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Preferred daily regimen:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">Azithromycin</a> 250 to 500 mg daily (or <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a> 1000 mg daily) PLUS</p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">Rifampin</a> 450 (for patients &lt;45 kg) or 600 mg (for patients &gt;45 kg) daily PLUS</p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">Ethambutol</a> 15 mg/kg daily</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Alternative daily regimen:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">Isoniazid</a> 300 mg daily PLUS</p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">Rifampin</a> 450 (for patients &lt;45 kg) or 600 mg (for patients &gt;45 kg) daily PLUS</p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">Ethambutol</a> 15 mg/kg daily</p><p></p><p class="bulletIndent1"><strong>OR</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An intermittently dosed regimen:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">Azithromycin</a> 500 mg (or <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a> 1000 mg) three times weekly PLUS</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">Rifampin</a> 450 (for patients &lt;45 kg) or 600 mg (for patients &gt;45 kg) three times weekly PLUS</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">Ethambutol</a> 25 mg/kg three times weekly</p><p></p><p>For individuals without cavitary disease, either an intermittently dosed regimen or a daily dosed regimen can be used; for those with cavitary disease, we favor a daily dosed regimen because of a lack of data on intermittently dosed regimens in that population [<a href="#rid4">4</a>]. </p><p><em>M. kansasii</em> treatment outcomes are generally good, with rare treatment failures and uncommon relapse [<a href="#rid14">14</a>]. There have been no randomized comparative trials evaluating treatment of <em>M. kansasii </em>lung disease, so recommendations are based on observational data as well as understanding of in vitro susceptibility. </p><p>Several studies have suggested good efficacy of the combination of a macrolide, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, and <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">ethambutol</a>. In a prospective study of 18 patients, a thrice-weekly <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a>, ethambutol, and rifampin-containing regimen, given for an average of 13.5 months, was effective, with no relapses during a mean follow-up of 46 months [<a href="#rid15">15</a>]. A larger retrospective study treated 56 patients with the same three-drug regimen administered daily for a median duration of 21 months; all patients were cured, but relapse rates were not reported [<a href="#rid9">9</a>]. A retrospective study from Korea reported similar treatment outcomes between 49 patients treated with a macrolide-based versus an isoniazid-based regimen [<a href="#rid16">16</a>]. Other preclinical studies support the efficacy of macrolide-containing regimens. In a murine model, clarithromycin was the most active single agent, followed by rifampin and <a class="drug drug_general" data-topicid="8928" href="/z/d/drug information/8928.html" rel="external">gatifloxacin</a> [<a href="#rid17">17</a>]. Clarithromycin plus rifampin was the most active combination. The fluoroquinolone <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">moxifloxacin</a> also has good in vitro activity against <em>M. kansasii</em>, although there are no clinical studies evaluating its use [<a href="#rid11">11,12,18</a>].</p><p>Most observational data have evaluated the combination of <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a>, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, and <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">ethambutol</a>, given for 9 to 18 months, which had traditionally been the most commonly used regimen [<a href="#rid19">19-24</a>]. In two studies that evaluated a 12-month treatment with this combination (supplemented for the first two to three months with parenteral <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">streptomycin</a>) cure was reported in 83 to 89 percent of patients with relapse rates of 2.5 to 6.6 percent [<a href="#rid19">19,23</a>]. </p><p>In other studies, <em>M. kansasii</em> infection has been associated with a more rapid culture conversion compared with other slowly growing NTM, and cure rates have ranged from 52 to 100 percent [<a href="#rid21">21,22,24</a>]. When non-mycobacterial deaths and patients lost to follow-up were excluded from the analysis, the cure rate was essentially 100 percent. In an observational study evaluating a two-drug regimen (<a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> and <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">ethambutol</a>) for nine months, cure rates were similarly high, but there was a somewhat higher relapse rate of 10 percent [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H727501369"><span class="h3">Rifampin-resistant isolates</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">Rifampin</a> should not be used in patients with infection with rifampin-resistant isolates. Instead, a regimen consisting of at least three drugs should be selected based on results of susceptibility testing. Data informing the selection of one alternative regimen over another are extremely limited.</p><p>For such cases, we prefer a regimen that includes either a macrolide (<a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> or <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a>) or <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">moxifloxacin</a> plus <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">ethambutol</a> and <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a>. The excellent in vitro activity of clarithromycin and moxifloxacin against <em>M. kansasii </em>[<a href="#rid12">12</a>]<em> </em>suggests that multidrug regimens containing these agents and other drugs based on in vitro susceptibilities are likely to be effective for treatment of a patient with rifampin-resistant <em>M. kansasii </em>disease. </p><p>Other options include a regimen of high-dose <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a> (900 mg/day), <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">ethambutol</a>, <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, and <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">streptomycin</a>. This regimen was associated with sputum clearance in 90 percent of treatment courses in a small study [<a href="#rid13">13</a>]. </p><p><a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">Linezolid</a> has good in vitro activity (MIC range ≤0.25 to 2 mcg/mL), but there is no clinical experience in treating <em>M. kansasii</em> disease [<a href="#rid10">10,12</a>].  </p><p class="headingAnchor" id="H2870024085"><span class="h2">Treatment duration</span><span class="headingEndMark"> — </span>Treatment should be continued for 12 months [<a href="#rid4">4</a>]. The high cure rates with rifampin-based regimens suggest that a shorter regimen may eventually be available. However, to date, regimens of less than 12 months duration have had unacceptably high relapse rates [<a href="#rid25">25</a>] or lower cure rates [<a href="#rid22">22</a>] than three-drug regimens (sometimes supplemented with <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">streptomycin</a>) given for 12 or more months.</p><p class="headingAnchor" id="H203378094"><span class="h2">Role of surgery</span><span class="headingEndMark"> — </span>In contrast to <em>M. avium</em> complex lung disease, the role of surgical intervention in the treatment of <em>M. kansasii</em> lung disease is minimal because of its high response to medical therapy. In very rare instances, surgical intervention may be useful for patients with fibrocavitary disease who fail therapy. Surgical treatment should only be undertaken by a team with substantial experience in treating NTM lung disease. </p><p class="headingAnchor" id="H990370277"><span class="h1">OTHER NONTUBERCULOUS MYCOBACTERIA</span><span class="headingEndMark"> — </span>Other slowly growing nontuberculous mycobacteria (NTM), including <em>M. malmoense, Mycobacterium simiae,</em> <em>Mycobacterium szulgai</em>, and <em>M. xenopi</em>, can also cause chronic lung disease. It is difficult to make generalities about the therapy of disease caused by these organisms because there have been few randomized trials for the treatment of most of these organisms. In addition, for most of these organisms, there is not a demonstrable correlation between in vitro susceptibility to a specific drug and in vivo response. As with <em>M. avium</em> complex (MAC), more effective drugs are needed to improve outcomes. </p><p class="headingAnchor" id="H1141620042"><span class="h2">M. malmoense</span><span class="headingEndMark"> — </span><em>M. malmoense </em>was first isolated in 1977 from respiratory specimens in four patients from Malmo, Sweden [<a href="#rid26">26</a>]. The organism is considered the second most pathogenic NTM after MAC in some parts of Northern Europe [<a href="#rid27">27,28</a>]. However, the clinical significance of <em>M. malmoense </em>is variable; in the Netherlands, 70 to 80 percent of isolates are considered clinically significant [<a href="#rid29">29</a>], whereas in the United States, <em>M. malmoense</em> is rarely a pathogen [<a href="#rid30">30</a>]. Disease typically occurs in a patient with underlying lung disease.</p><p class="headingAnchor" id="H4038675775"><span class="h3">In vitro susceptibility</span><span class="headingEndMark"> — </span><em>M. malmoense</em> is a slowly growing non-pigmented mycobacteria that grows optimally at a pH of 6.0 [<a href="#rid31">31</a>]. Determination of drug susceptibility has been variable with poor correlation with clinical outcomes [<a href="#rid32">32-34</a>]. The initial strains were reported to be susceptible to <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">ethambutol</a>, <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">ethionamide</a>, kanamycin, and <a class="drug drug_general" data-topicid="9309" href="/z/d/drug information/9309.html" rel="external">cycloserine</a> and resistant to <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a>, <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">streptomycin</a>, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, and p-amino-salicylic acid. However, more recent data using an agar dilution method described susceptibility to rifampin, <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">rifabutin</a>, <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a>, cycloserine, <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">clofazimine</a>, and prothionamide [<a href="#rid35">35</a>]. Isolates were usually resistant to isoniazid, streptomycin, <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">amikacin</a>, and <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a>. </p><p class="headingAnchor" id="H3937073951"><span class="h3">Regimen selection</span><span class="headingEndMark"> — </span>The optimal treatment regimen is uncertain [<a href="#rid36">36</a>]. We suggest a three-drug combination consisting of the following:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">Azithromycin</a> 250 to 500 mg daily (or <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a> 1000 mg daily) PLUS</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">Rifampin</a> 450 to 600 mg daily PLUS</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">Ethambutol</a> 15 mg/kg daily</p><p></p><p>For patients with more severe disease, such as fibrocavitary disease, we also include one of the following agents: </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">Moxifloxacin</a> 400 mg daily OR</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">Amikacin</a> 15 mg/kg intravenously three times weekly</p><p></p><p>Treatment should be continued until sputum cultures are consecutively negative for at least 12 months.</p><p>Evidence supporting treatment regimens for pulmonary disease due to <em>M. malmoense</em> is limited mainly to two randomized pragmatic multicenter trials conducted by the British Thoracic Society [<a href="#rid32">32,37</a>]. In these studies, although not directly compared, certain three-drug regimens were associated with lower treatment failure and relapse rates than two-drug regimens (5 percent versus 12 percent). Among three-drug regimens, a macrolide-containing regimen compared with a fluoroquinolone-containing regimen resulted in a higher proportion of patients alive and cured at five years and was better tolerated. However, many of the differences in outcomes between the different arms of the two studies were modest and not statistically significant. Importantly, development of drug resistance was not reported.</p><p class="bulletIndent1"><span class="glyph">●</span>In the one trial [<a href="#rid37">37</a>], <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a>, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, plus <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">ethambutol</a> was compared with a regimen of <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a>, rifampin, and ethambutol. Overall, the macrolide-containing regimen had slightly better outcomes, with 38 percent alive and cured at given years compared with 20 percent with the ciprofloxacin regimen. Treatment failure occurred in 5 percent of patients in both study groups. All-cause mortality was high; 42 percent in the clarithromycin group versus 56 percent in the ciprofloxacin arm. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a previous trial, treatment with <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> plus <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">ethambutol</a> (two-drug regimen) was statistically equivalent to treatment with rifampin plus ethambutol plus <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a> (three-drug regimen), with 38 and 44 percent of patients alive and cured at five years, respectively [<a href="#rid32">32</a>]. Treatment failure occurred in 12 percent of patients in the two-drug arm versus 9 percent in the three-drug arm. All-cause mortality was 33 to 35 percent in both arms whereas mycobacterial-related deaths occurred in 2 percent of the two-drug arm versus 6 percent in the three-drug arm. </p><p></p><p>In a retrospective study of 30 patients from the Netherlands with pulmonary <em>M. malmoense</em> disease, the overall clinical response to treatment (with various, usually macrolide-containing regimens) was good; 70 percent had an adequate response, 17 percent suffered a failure or relapse, and 13 percent died [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H3814192300"><span class="h2">M. simiae</span><span class="headingEndMark"> — </span><em>M. simiae</em> was reported in 1965 by Karassova after the organism was isolated from rhesus monkeys [<a href="#rid38">38</a>]. The organism is typically found in water and has been reported most commonly from arid areas such as the desert southwestern United States and Israel [<a href="#rid2">2</a>]. In various cohorts, including from the US and Netherlands, fewer than 25 percent of <em>M. simiae</em> isolates are thought to be clinically significant [<a href="#rid39">39-42</a>]. Thus,<em> </em>when <em>M. simiae</em> is isolated in clinical samples, it more often a contaminant than a true pathogen. When it is a true pathogen, however, it is extremely difficult to treat effectively due to high levels of in vitro resistance.</p><p class="headingAnchor" id="H1296794917"><span class="h3">In vitro susceptibility</span><span class="headingEndMark"> — </span><em>M. simiae</em> typically displays high levels of in vitro resistance to antimycobacterial drugs. In vitro resistance has been reported for <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">rifabutin</a>, <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">ethambutol</a>, <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a>, <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">streptomycin</a>, <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">amikacin</a>, and <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">ethionamide</a>, and resistance to <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a> and <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> has been reported in over 70 percent of isolates [<a href="#rid35">35,43</a>]. Among 29 isolates from the Netherlands, most were susceptible to <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">clofazimine</a>, <a class="drug drug_general" data-topicid="9309" href="/z/d/drug information/9309.html" rel="external">cycloserine</a>, and prothionamide [<a href="#rid35">35</a>]. No synergy can be demonstrated between rifampin and ethambutol [<a href="#rid34">34</a>]; however, in vitro synergy was described between clofazimine and amikacin [<a href="#rid44">44</a>]. </p><p class="headingAnchor" id="H1071623567"><span class="h3">Regimen selection</span><span class="headingEndMark"> — </span>The optimal treatment regimen is uncertain. We suggest a three-drug combination consisting of the following:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">Azithromycin</a> 250 to 500 mg daily (or <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a> 1000 mg daily) PLUS</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">Moxifloxacin</a> 400 mg daily PLUS</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">Trimethoprim-sulfamethoxazole</a> 1 DS tablet twice daily</p><p></p><p>For patients with fibrocavitary disease, because of the high level of in vitro resistance and documented in vitro synergy between <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">clofazimine</a> and <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">amikacin</a> [<a href="#rid44">44</a>], we supplement the regimen with clofazimine or clofazimine plus amikacin, if feasible based on availability and expected toxicity. In the United States, clofazimine is not commercially available but  through an expanded-access program or single-patient investigational new drug application. </p><p>Treatment should be continued until sputum cultures are consecutively negative for at least 12 months.</p><p>To date, although many regimens have been tried, there are no predictably effective drug combinations for treating <em>M. simiae</em>, and treatment outcomes have varied significantly between reports. Limited evidence suggests that the regimen suggested above is promising. In a study from Iran, treatment with <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a>, <a class="drug drug_general" data-topicid="9715" href="/z/d/drug information/9715.html" rel="external">ofloxacin</a>, and <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> was effective in 24 of 26 patients with <em>M. simiae</em> pulmonary disease [<a href="#rid45">45</a>]. There were no recurrences in the cured patients during two years of follow-up. Treatment with a similar regimen (substituting <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">moxifloxacin</a> for ofloxacin) at the time of lung transplant for a patient with a chronic <em>M. simiae</em> infection resulted in good outcomes, with negative cultures at one year [<a href="#rid46">46</a>]. Similarly, in a patient with HIV/AIDS, the combination of clarithromycin, <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">ethambutol</a>, and <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> successfully treated <em>M. simiae</em> infection [<a href="#rid47">47</a>].</p><p>In a study of 102 patients with pulmonary <em>M. simiae</em> in Israel, all were treated with <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> (600 mg), <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a> (1000 mg), <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">ethambutol</a> (25 mg/kg for the first two months, then 15 mg/kg) [<a href="#rid48">48</a>]. Patients were treated for at least 12 months of negative cultures. There were no failures or relapses reported; there were five non-mycobacterial deaths during a median of 24 months of follow-up. However, others have described much poorer treatment outcomes with similar regimens, which is consistent with our clinical experience [<a href="#rid2">2</a>]. </p><p>Preclinical studies have also suggested possible effective regimens. In an intravenous murine model, a combination of <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">clofazimine</a>, and <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">amikacin</a> demonstrated activity against two strains of <em>M. simiae</em> [<a href="#rid49">49</a>]. In a disseminated murine model, <a class="drug drug_general" data-topicid="9715" href="/z/d/drug information/9715.html" rel="external">ofloxacin</a> and <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a> plus <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">ethambutol</a> were more active than clarithromycin alone [<a href="#rid50">50</a>].</p><p class="headingAnchor" id="H2807893475"><span class="h2">M. szulgai</span><span class="headingEndMark"> — </span><em>M. szulgai</em> was first described in 1972 in seven patients with pulmonary and extrapulmonary disease [<a href="#rid51">51</a>]. Pulmonary <em>M. szulgai</em> disease is rare, but <em>M. szulgai</em> isolates are often clinically significant. Among 21 patients with <em>M. szulgai</em> isolation in the Netherlands, 76 percent were felt to be clinically significant [<a href="#rid39">39</a>]. Similarly, in a previous study from the United States, 57 percent of patients with <em>M. szulgai</em> were thought to be significant [<a href="#rid52">52</a>]. However, in South Korea, only 43 percent of patients had clinically significant disease [<a href="#rid53">53</a>]. Disease occurs most commonly in patients with underlying lung disease, and the presentation is similar to pulmonary tuberculosis. </p><p class="headingAnchor" id="H851533254"><span class="h3">In vitro susceptibility</span><span class="headingEndMark"> — </span><em>M. szulgai</em> is often susceptible to a broad array of antibiotics including <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">rifabutin</a>, <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">ethionamide</a>, prothionamide, aminoglycosides, fluoroquinolones, macrolides, <a class="drug drug_general" data-topicid="9309" href="/z/d/drug information/9309.html" rel="external">cycloserine</a>, and <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">clofazimine</a>. The organism is usually resistant to <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a> in vitro [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H558283925"><span class="h3">Regimen selection</span><span class="headingEndMark"> — </span>The optimal regimen is uncertain, but most patients respond well to multidrug therapy. We suggest the following three-drug combination regimen:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">Azithromycin</a> 250 to 500 mg daily (or <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a> 1000 mg daily)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">Rifampin</a> 450 to 600 mg daily (or <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">rifabutin</a> 300 mg daily)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">Ethambutol</a> 15 mg/kg daily</p><p></p><p>Based on in vitro drug susceptibility test results, later generation fluoroquinolones such as <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">moxifloxacin</a> can be substituted for one of the above drugs.</p><p>Treatment should be continued until sputum cultures are consecutively negative for at least 12 months. Although shorter regimens may be possible, the number of patients described with regimens less than 12 months is too small to draw definitive conclusions.</p><p>Although the optimal treatment regimen has not been identified through randomized trials, most patients can be treated successfully with a macrolide-containing regimen that includes more than two drugs [<a href="#rid39">39,54-57</a>]. In a study that included 12 patients who were treated for <em>M. szulgai</em> infection, patients responded well to multiple treatment regimens, usually including <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">ethambutol</a>, and either <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a> or <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> [<a href="#rid39">39</a>]. In a small retrospective study from South Korea, the median duration of treatment was 8 months and all 9 patients that were treated responded well with no relapses after a median follow-up of 41 months [<a href="#rid53">53</a>]. Eight of nine patients were treated with <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a>, rifampin, and ethambutol and one with <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a>, rifampin, and ethambutol. </p><p class="headingAnchor" id="H2671357252"><span class="h2">M. xenopi</span><span class="headingEndMark"> — </span><em>M. xenopi</em> was identified in 1959 from lesions on the skin of a South African toad [<a href="#rid58">58</a>]. The organism is one of the most common causes of pulmonary disease due to an NTM in some parts of Canada and Europe [<a href="#rid3">3,27,59,60</a>]. In the Netherlands, approximately 50 percent of isolates are reported to be clinically significant and most patients have underlying lung disease or other co-morbidities [<a href="#rid61">61</a>]. Based on a study from France, approximately one-third of patients present with cavitary disease, one-third with a solitary nodule, and one-third with an infiltrative form that is associated with a higher mortality rate [<a href="#rid62">62</a>]. Prognosis of patients with <em>M. xenopi</em> infection is poor with mortality rates ranging from 51 to 69 percent at five years [<a href="#rid32">32,62</a>]. </p><p class="headingAnchor" id="H770436215"><span class="h3">In vitro susceptibility</span><span class="headingEndMark"> — </span>Drug susceptibility results may be difficult to interpret and reports on susceptibility are not entirely consistent. Furthermore, there is poor correlation between in vitro activity and clinical outcomes. </p><p>In a study of 35 isolates in Italy, approximately 75 percent were susceptible to <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a>, <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">ethambutol</a>, and <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">streptomycin</a> [<a href="#rid63">63</a>]. Among 50 isolates from the Netherlands, most were susceptible to rifampin, <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">rifabutin</a>, streptomycin, <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">amikacin</a>, <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a>, <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a>, <a class="drug drug_general" data-topicid="9309" href="/z/d/drug information/9309.html" rel="external">cycloserine</a>, <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">clofazimine</a>, and prothionamide, but were resistant to isoniazid and <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">ethionamide</a> [<a href="#rid35">35</a>].</p><p>In another study from France, <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a> and <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">moxifloxacin</a> had the lowest minimum inhibitory concentration (MIC) values with all combinations tested showing synergism; amikacin-containing regimens demonstrated the greatest synergist activity [<a href="#rid64">64</a>]. </p><p>Time-kill kinetics demonstrate similar activity of <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a> and <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">moxifloxacin</a> [<a href="#rid65">65</a>].</p><p class="headingAnchor" id="H667687060"><span class="h3">Regimen selection</span><span class="headingEndMark"> — </span>The optimal treatment for <em>M. xenopi</em> has not been established [<a href="#rid2">2</a>]. Treatment of pulmonary disease is associated with high all-cause mortality and there is poor correlation between in vitro activity and clinical outcomes. We suggest use of at least three drugs, including:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">Azithromycin</a> 250 to 500 mg daily (or <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a> 1000 mg daily) or <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">moxifloxacin</a> 400 mg daily PLUS </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">Rifampin</a> 450 to 600 mg daily (or <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">rifabutin</a> 300 mg daily) PLUS</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">Ethambutol</a> 15 mg/kg daily</p><p></p><p>Either a macrolide or moxifloxacin-based regimen can be used. We use whichever drug has the best in vitro activity on susceptibility testing of the isolate, recognizing the limitations of such testing with <em>M. xenopi</em>. </p><p>For patients with fibrocavitary disease, we add <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">amikacin</a>, 15 mg/kg administered intravenously three times weekly.</p><p>Treatment should be continued until sputum cultures are consecutively negative for at least 12 months.</p><p>Our recommendations differ slightly from the British Thoracic Society guidelines, which recommend a four-drug regimen, including a macrolide, <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">ethambutol</a>, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, with either a fluoroquinolone or <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a> [<a href="#rid66">66</a>]. For patients with extensive fibrocavitary disease, a four-drug regimen is reasonable, and we would use a fluoroquinolone instead of isoniazid given the much better in vitro activity of the fluoroquinolones against <em>M. xenopi</em> [<a href="#rid35">35</a>]. </p><p>A randomized, placebo-controlled study comparing macrolide- and fluoroquinolone-based regimens has been completed in France, but results are not yet available. Otherwise, evidence supporting the use of different regimens for <em>M. xenopi</em> come mainly from observational studies [<a href="#rid14">14,60</a>]. In a systematic review that included 48 studies and 1255 subjects, the overall treatment success at the end of therapy was 80 percent, with a 15 percent relapse rate; thus, 65 percent had a sustained, disease-free outcome [<a href="#rid60">60</a>]. Multiple drug regimens were used in these studies. INH-containing and aminoglycoside-containing regimens were associated with worse short- and long-term success whereas fluoroquinolone-containing regimens were associated with better long-term success. </p><p>Data from other studies have not suggested superiority of particular regimens. Two trials of two- and three-drug regimens reported overall poor results [<a href="#rid32">32,37</a>]. As an example, in a trial conducted by the British Thoracic Society that compared <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a> and <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a>, each in combination with <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> and <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">ethambutol</a>, only 18 and 12 percent of patients, respectively, were alive and cured at five years [<a href="#rid37">37</a>]. In a retrospective study of 136 patients with pulmonary infection caused by <em>M. xenopi</em>, median survival was 10 months in untreated patients compared with 32 months in treated patients, and combination therapy with a rifamycin-containing regimen was associated with improved survival rates [<a href="#rid62">62</a>]. However, since these outcomes were not adjusted for comorbidity, the differences in survival cannot be definitively attributed to treatment. In a report on 49 patients with <em>M. xenopi</em> lung disease in the Netherlands, multiple different treatment regimens were used, but no specific drug combination showed consistently superior results [<a href="#rid61">61</a>].</p><p>Preclinical studies have also been used to inform appropriate regimen selection. In an intravenous mouse model, multiple different clarithromycin-containing regimens including <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a> alone showed more activity than a combination of <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a>, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, and <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">ethambutol</a> [<a href="#rid67">67</a>]. <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">Azithromycin</a> was demonstrated to be more active than clarithromycin in beige mice, and both macrolides were comparable to or better than rifampin, ethambutol, or <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">clofazimine</a> [<a href="#rid68">68</a>]. The combination of ethambutol and rifampin plus either clarithromycin or <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">moxifloxacin</a> had significant bactericidal activity after 12 weeks of therapy in a nude mouse aerosol model [<a href="#rid64">64</a>]. Amikacin-containing regimens had the highest efficacy against <em>M. xenopi</em> in this model.</p><p class="headingAnchor" id="H4019483762"><span class="h1">MONITORING</span></p><p class="headingAnchor" id="H2418120523"><span class="h2">Monitoring for side effects</span><span class="headingEndMark"> — </span>Patients should be evaluated clinically for evidence of drug-related toxicity every one to two months while on therapy. This includes testing of the complete blood count, blood urea nitrogen (BUN), creatinine, and liver enzymes. For patients receiving aminoglycosides, audiograms and vestibular assessment should be performed routinely with the frequency of monitoring depending on the dose used and whether the patient has pre-existing hearing loss. Other specific testing depends on the drugs included in the regimen. As an example, color discrimination and visual acuity should be evaluated regularly in patients on <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">ethambutol</a> or <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a>. </p><p class="bulletIndent1"><span class="glyph">●</span>Gastrointestinal intolerance – <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a>, <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a>, fluoroquinolones, <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a>, <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">ethambutol</a>, <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">rifabutin</a>, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, or <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">clofazimine</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal liver function tests – <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a>, <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a>, <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a>, <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">moxifloxacin</a>, <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">rifabutin</a>, or <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Low white blood cell count – <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">rifabutin</a>, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Impaired visual acuity or color vision – <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">ethambutol</a>, <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Decreased auditory function – aminoglycosides, <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a>, or <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vestibular toxicity – aminoglycosides</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Decreased renal function – aminoglycosides</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral neuropathy – <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a>, <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">ethambutol</a>, aminoglycosides, <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prolonged QTc – fluoroquinolones, macrolides, <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">clofazimine</a></p><p></p><p>Decisions on dose modifications or drug discontinuations in the setting of toxicity are complex and depend on the type and severity of the toxicity and the importance of the offending drug in the patient's regimen. The threshold to discontinue a macrolide because of mild or moderate transaminitis is generally higher than that for discontinuation of <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">ethambutol</a> in the setting of objective visual deficits. Similarly, the decision to stop an aminoglycoside must be weighed against the risks and benefits to the patient. Consultation with an expert in nontuberculous mycobacterial infections is advised in such situations. </p><p class="headingAnchor" id="H39487628"><span class="h2">Monitoring for clinical response</span><span class="headingEndMark"> — </span>The duration of treatment for most NTM-related pulmonary disease is determined by the microbiologic response to therapy, with the aim of achieving 12 months of negative sputum cultures. Therefore, we typically obtain acid-fast bacillus (AFB) sputum cultures every one to two months to monitor treatment efficacy and less often once sustained conversion has been documented. If the patient is not productive of sputum, we recommend a sputum induction with hypertonic <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>. The likelihood of conversion to negative cultures is unlikely within the first few months of therapy for most pulmonary nontuberculous mycobacteria (NTM) species. However, earlier documentation of sputum conversion allows optimization of treatment duration, which is based on the length of time with negative cultures.</p><p>Lack of microbiological response after six months of therapy warrants evaluation for adherence to the drug regimen, susceptibility testing, and possible assessment of serum drug concentrations.</p><p class="headingAnchor" id="H3492190447"><span class="h2">Therapeutic drug monitoring</span><span class="headingEndMark"> — </span>The role of TDM in the management of patients with NTM infections remains unclear. (See  <a class="medical medical_review" href="/z/d/html/5341.html" rel="external">"Treatment of <i>Mycobacterium avium </i>complex pulmonary infection in adults", section on 'Therapeutic drug monitoring'</a>.)</p><p class="headingAnchor" id="H1339191476"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113062.html" rel="external">"Society guideline links: Nontuberculous mycobacteria"</a>.)</p><p class="headingAnchor" id="H2198279036"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>After <em>Mycobacterium avium</em> complex (MAC), the most common slow-growing nontuberculous mycobacteria (NTM) to cause lung disease are <em>Mycobacterium kansasii</em>, <em>Mycobacterium malmoense, </em>and<em> Mycobacterium xenopi</em>, depending on the geographic area. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Untreated <em>M. kansasii</em> infection usually leads to chronic progressive lung disease, and treatment outcomes are generally good, with rare treatment failures and uncommon relapse. (See <a class="local">'Rationale for treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with <em>M. kansasii</em> lung disease, we suggest treatment with <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a>, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, and <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">ethambutol</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Rifampin should not be used in patients with infection with rifampin-resistant isolates. Instead, a regimen consisting of at least three drugs (such as a macrolide or <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">moxifloxacin</a> plus ethambutol and <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a>) should be selected based on susceptibility testing results. (See <a class="local">'Regimen selection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For lung disease caused by other slowly growing NTM, including <em>M. malmoense, Mycobacterium simiae,</em> <em>Mycobacterium szulgai</em>, and <em>M. xenopi</em>, only limited clinical evidence informs the choice of an antimycobacterial regimen. Furthermore, for most of them, in vitro susceptibility to a specific drug does not correlate with in vivo responses.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The clinical significance of <em>M. malmoense</em> is geographically variable; it is a relatively frequent pathogen in Northern Europe but is rarely so in the United States. For <em>M. malmoense</em> infection, we suggest a macrolide plus <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> plus <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">ethambutol</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). An additional agent is warranted for severe or fibrocavitary disease. (See <a class="local">'M. malmoense'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><em>M. simiae</em>, when isolated in clinical samples, is more often a contaminant than a true pathogen. When it does cause symptomatic infection, however, it is extremely difficult to treat effectively. For <em>M. simiae</em> infection, we suggest a macrolide plus <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">moxifloxacin</a> plus <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Additional agents are warranted for severe or fibrocavitary disease. (See <a class="local">'M. simiae'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pulmonary <em>M. szulgai</em> disease is rare, but <em>M. szulgai</em> isolates are often clinically significant. Most infections respond well to multidrug therapy. For <em>M. szulgai</em> infection, we suggest a macrolide plus <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> plus <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">ethambutol</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'M. szulgai'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><em>M. xenopi</em> is one of the most common causes of NTM pulmonary disease in some parts of Canada and Europe; prognosis is poor. For <em>M. xenopi </em>infection, we suggest using at least three drugs, including a macrolide and/or <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">moxifloxacin</a> plus <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> plus <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">ethambutol</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). An additional agent is warranted for severe or fibrocavitary disease. (See <a class="local">'M. xenopi'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For most NTM lung disease, treatment is continued until sputum cultures are consecutively negative for at least 12 months. Pulmonary disease caused by <em>M. kansasii </em>is treated for a fixed duration of 12 months. (See <a class="local">'Treatment duration'</a> above and <a class="local">'Other nontuberculous mycobacteria'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We typically obtain sputum cultures every one to two months following treatment initiation to monitor treatment response. Patients should also be evaluated clinically for evidence of drug-related toxicity every one to two months while on therapy. This generally includes testing of the complete blood count, blood urea nitrogen (BUN) and creatinine, liver enzymes, as well as color discrimination and visual acuity. (See <a class="local">'Monitoring'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Wolinsky E. Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis 1979; 119:107.</a></li><li><a class="nounderline abstract_t">Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367.</a></li><li><a class="nounderline abstract_t">Hoefsloot W, van Ingen J, Andrejak C, et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J 2013; 42:1604.</a></li><li><a class="nounderline abstract_t">Daley CL, Iaccarino JM, Lange C, et al. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clin Infect Dis 2020; 71:e1.</a></li><li><a class="nounderline abstract_t">BUHLER VB, POLLAK A. Human infection with atypical acid-fast organisms; report of two cases with pathologic findings. Am J Clin Pathol 1953; 23:363.</a></li><li><a class="nounderline abstract_t">Francis PB, Jay SJ, Johanson WG Jr. The course of untreated Mycobacterium kansasii disease. Am Rev Respir Dis 1975; 111:477.</a></li><li><a class="nounderline abstract_t">Ahn CH, Wallace RJ Jr, Steele LC, Murphy DT. Sulfonamide-containing regimens for disease caused by rifampin-resistant Mycobacterium kansasii. Am Rev Respir Dis 1987; 135:10.</a></li><li><a class="nounderline abstract_t">Pezzia W, Raleigh JW, Bailey MC, et al. Treatment of pulmonary disease due to Mycobacterium kansasii: recent experience with rifampin. Rev Infect Dis 1981; 3:1035.</a></li><li><a class="nounderline abstract_t">Shitrit D, Baum GL, Priess R, et al. Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome. Chest 2006; 129:771.</a></li><li><a class="nounderline abstract_t">Brown-Elliott BA, Crist CJ, Mann LB, et al. In vitro activity of linezolid against slowly growing nontuberculous Mycobacteria. Antimicrob Agents Chemother 2003; 47:1736.</a></li><li><a class="nounderline abstract_t">Guna R, Muñoz C, Domínguez V, et al. In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii. J Antimicrob Chemother 2005; 55:950.</a></li><li><a class="nounderline abstract_t">Alcaide F, Calatayud L, Santín M, Martín R. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii. Antimicrob Agents Chemother 2004; 48:4562.</a></li><li><a class="nounderline abstract_t">Wallace RJ Jr, Dunbar D, Brown BA, et al. Rifampin-resistant Mycobacterium kansasii. Clin Infect Dis 1994; 18:736.</a></li><li><a class="nounderline abstract_t">Diel R, Ringshausen F, Richter E, et al. Microbiological and Clinical Outcomes of Treating Non-Mycobacterium Avium Complex Nontuberculous Mycobacterial Pulmonary Disease: A Systematic Review and Meta-Analysis. Chest 2017; 152:120.</a></li><li><a class="nounderline abstract_t">Griffith DE, Brown-Elliott BA, Wallace RJ Jr. Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study. Clin Infect Dis 2003; 37:1178.</a></li><li><a class="nounderline abstract_t">Moon SM, Choe J, Jhun BW, et al. Treatment with a macrolide-containing regimen for Mycobacterium kansasii pulmonary disease. Respir Med 2019; 148:37.</a></li><li><a class="nounderline abstract_t">Cynamon MH, Elliott SA, DeStefano MS, Yeo AE. Activity of clarithromycin alone and in combination in a murine model of Mycobacterium kansasii infection. J Antimicrob Chemother 2003; 52:306.</a></li><li><a class="nounderline abstract_t">Rodriguez Díaz JC, López M, Ruiz M, Royo G. In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria. Int J Antimicrob Agents 2003; 21:585.</a></li><li><a class="nounderline abstract_t">Ahn CH, Lowell JR, Ahn SS, et al. Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii. Am Rev Respir Dis 1983; 128:1048.</a></li><li><a class="nounderline abstract_t">Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Research Committee, British Thoracic Society. Thorax 1994; 49:442.</a></li><li><a class="nounderline abstract_t">Sauret J, Hernández-Flix S, Castro E, et al. Treatment of pulmonary disease caused by Mycobacterium kansasii: results of 18 vs 12 months' chemotherapy. Tuber Lung Dis 1995; 76:104.</a></li><li><a class="nounderline abstract_t">Evans SA, Colville A, Evans AJ, et al. Pulmonary Mycobacterium kansasii infection: comparison of the clinical features, treatment and outcome with pulmonary tuberculosis. Thorax 1996; 51:1248.</a></li><li><a class="nounderline abstract_t">Santin M, Dorca J, Alcaide F, et al. Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease. Eur Respir J 2009; 33:148.</a></li><li><a class="nounderline abstract_t">Park HK, Koh WJ, Shim TS, Kwon OJ. Clinical characteristics and treatment outcomes of Mycobacterium kansasii lung disease in Korea. Yonsei Med J 2010; 51:552.</a></li><li><a class="nounderline abstract_t">Pulmonary disease caused by Mycobacterium avium-intracellulare in HIV-negative patients: five-year follow-up of patients receiving standardised treatment. Int J Tuberc Lung Dis 2002; 6:628.</a></li><li><a class="nounderline abstract_t">Schröder KH, Juhlin I. Mycobacterium malmoense sp. nov. J Syst Bacteriol 1977; 27:241.</a></li><li><a class="nounderline abstract_t">Martín-Casabona N, Bahrmand AR, Bennedsen J, et al. Non-tuberculous mycobacteria: patterns of isolation. A multi-country retrospective survey. Int J Tuberc Lung Dis 2004; 8:1186.</a></li><li><a class="nounderline abstract_t">Henriques B, Hoffner SE, Petrini B, et al. Infection with Mycobacterium malmoense in Sweden: report of 221 cases. Clin Infect Dis 1994; 18:596.</a></li><li><a class="nounderline abstract_t">Hoefsloot W, van Ingen J, de Lange WC, et al. Clinical relevance of Mycobacterium malmoense isolation in The Netherlands. Eur Respir J 2009; 34:926.</a></li><li><a class="nounderline abstract_t">Buchholz UT, McNeil MM, Keyes LE, Good RC. Mycobacterium malmoense infections in the United States, January 1993 through June 1995. Clin Infect Dis 1998; 27:551.</a></li><li><a class="nounderline abstract_t">Heginbothom ML, Lindholm-Levy PJ, Heifets LB. Susceptibilities of Mycobacterium malmoense determined at the growth optimum pH (pH 6.0). Int J Tuberc Lung Dis 1998; 2:430.</a></li><li><a class="nounderline abstract_t">Pulmonary disease caused by M. malmoense in HIV negative patients: 5-yr follow-up of patients receiving standardised treatment. Eur Respir J 2003; 21:478.</a></li><li><a class="nounderline abstract_t">Brown-Elliott BA, Nash KA, Wallace RJ Jr. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin Microbiol Rev 2012; 25:545.</a></li><li><a class="nounderline abstract_t">van Ingen J, Boeree MJ, van Soolingen D, Mouton JW. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist Updat 2012; 15:149.</a></li><li><a class="nounderline abstract_t">van Ingen J, van der Laan T, Dekhuijzen R, et al. In vitro drug susceptibility of 2275 clinical non-tuberculous Mycobacterium isolates of 49 species in The Netherlands. Int J Antimicrob Agents 2010; 35:169.</a></li><li><a class="nounderline abstract_t">Lange C, Bottger EC, Cambau E, et al. Consensus management recommendations for additional nontuberculous mycobacterial pulmonary diseases. Lancet Infect Dis (in press) 2022.</a></li><li><a class="nounderline abstract_t">Jenkins PA, Campbell IA, Banks J, et al. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. Thorax 2008; 63:627.</a></li><li><a class="nounderline abstract_t">Karassova V, Weissfeiler J, Krasznay E. Occurrence of atypical mycobacteria in Macacus rhesus. Acta Microbiol Acad Sci Hung 1965; 12:275.</a></li><li><a class="nounderline abstract_t">van Ingen J, Boeree MJ, de Lange WC, et al. Clinical relevance of Mycobacterium szulgai in The Netherlands. Clin Infect Dis 2008; 46:1200.</a></li><li><a class="nounderline abstract_t">Valero G, Peters J, Jorgensen JH, Graybill JR. Clinical isolates of Mycobacterium simiae in San Antonio, Texas. An 11-yr review. Am J Respir Crit Care Med 1995; 152:1555.</a></li><li><a class="nounderline abstract_t">Coolen-Allou N, Touron T, Belmonte O, et al. Clinical, Radiological, and Microbiological Characteristics of Mycobacterium simiae Infection in 97 Patients. Antimicrob Agents Chemother 2018; 62.</a></li><li><a class="nounderline abstract_t">Jabbour JF, Hamieh A, Sharara SL, Kanj SS. Mycobacterium simiae: Harmless colonizer or deadly pathogen? PLoS Pathog 2020; 16:e1008418.</a></li><li><a class="nounderline abstract_t">van Ingen J, Boeree MJ, Dekhuijzen PN, van Soolingen D. Clinical relevance of Mycobacterium simiae in pulmonary samples. Eur Respir J 2008; 31:106.</a></li><li><a class="nounderline abstract_t">van Ingen J, Totten SE, Helstrom NK, et al. In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease. Antimicrob Agents Chemother 2012; 56:6324.</a></li><li><a class="nounderline abstract_t">Baghaei P, Tabarsi P, Farnia P, et al. Pulmonary disease caused by Mycobacterium simiae in Iran's national referral center for tuberculosis. J Infect Dev Ctries 2012; 6:23.</a></li><li><a class="nounderline abstract_t">Qvist T, Katzenstein TL, Lillebaek T, et al. First report of lung transplantation in a patient with active pulmonary Mycobacterium simiae infection. Transplant Proc 2013; 45:803.</a></li><li><a class="nounderline abstract_t">Barzilai A, Rubinovich B, Blank-Porat D, et al. Successful treatment of disseminated Mycobacterium simiae infection in AIDS patients. Scand J Infect Dis 1998; 30:143.</a></li><li><a class="nounderline abstract_t">Shitrit D, Peled N, Bishara J, et al. Clinical and radiological features of Mycobacterium kansasii infection and Mycobacterium simiae infection. Respir Med 2008; 102:1598.</a></li><li><a class="nounderline abstract_t">Watson SR, Auclair LK, Collins FM. The effect of combined chemotherapy on suppressor T-cell activity in Mycobacterium simiae-infected mice. Immunology 1981; 43:459.</a></li><li><a class="nounderline abstract_t">Valero G, Moreno F, Graybill JR. Activities of clarithromycin, ofloxacin, and clarithromycin plus ethambutol against Mycobacterium simiae in murine model of disseminated infection. Antimicrob Agents Chemother 1994; 38:2676.</a></li><li><a class="nounderline abstract_t">Marks J, Jenkins PA, Tsukamura M. Mycobacterium szulgai--a new pathogen. Tubercle 1972; 53:210.</a></li><li><a class="nounderline abstract_t">O'Brien RJ, Geiter LJ, Snider DE Jr. The epidemiology of nontuberculous mycobacterial diseases in the United States. Results from a national survey. Am Rev Respir Dis 1987; 135:1007.</a></li><li><a class="nounderline abstract_t">Yoo H, Jeon K, Kim SY, et al. Clinical significance of Mycobacterium szulgai isolates from respiratory specimens. Scand J Infect Dis 2014; 46:169.</a></li><li><a class="nounderline abstract_t">Kitada S, Uenami T, Yoshimura K, et al. Long-term radiographic outcome of nodular bronchiectatic Mycobacterium avium complex pulmonary disease. Int J Tuberc Lung Dis 2012; 16:660.</a></li><li><a class="nounderline abstract_t">Sánchez-Alarcos JM, De Miguel-Díez J, Bonilla I, et al. Pulmonary infection due to Mycobacterium szulgai. Respiration 2003; 70:533.</a></li><li><a class="nounderline abstract_t">Benator DA, Kan V, Gordin FM. Mycobacterium szulgai infection of the lung: case report and review of an unusual pathogen. Am J Med Sci 1997; 313:346.</a></li><li><a class="nounderline abstract_t">Inomata S, Tanaka H, Nakajima K, et al. Pulmonary nontuberculous mycobacterial infection caused by Mycobacterium szulgai in a young healthy woman. Intern Med 2006; 45:913.</a></li><li><a class="nounderline abstract_t">SCHWABACHER H. A strain of Mycobacterium isolated from skin lesions of a cold-blooded animal, Xenopus laevis, and its relation to atypical acid-fast bacilli occurring in man. J Hyg (Lond) 1959; 57:57.</a></li><li><a class="nounderline abstract_t">Dailloux M, Abalain ML, Laurain C, et al. Respiratory infections associated with nontuberculous mycobacteria in non-HIV patients. Eur Respir J 2006; 28:1211.</a></li><li><a class="nounderline abstract_t">Varadi RG, Marras TK. Pulmonary Mycobacterium xenopi infection in non-HIV-infected patients: a systematic review. Int J Tuberc Lung Dis 2009; 13:1210.</a></li><li><a class="nounderline abstract_t">van Ingen J, Boeree MJ, de Lange WC, et al. Mycobacterium xenopi clinical relevance and determinants, the Netherlands. Emerg Infect Dis 2008; 14:385.</a></li><li><a class="nounderline abstract_t">Andréjak C, Lescure FX, Pukenyte E, et al. Mycobacterium xenopi pulmonary infections: a multicentric retrospective study of 136 cases in north-east France. Thorax 2009; 64:291.</a></li><li><a class="nounderline abstract_t">Manfredi R, Nanetti A, Morelli S, et al. A decade surveillance study of Mycobacterium xenopi disease and antimicrobial susceptibility levels in a reference teaching hospital of northern Italy: HIV-associated versus non-HIV-associated infection. HIV Clin Trials 2004; 5:206.</a></li><li><a class="nounderline abstract_t">Andréjak C, Almeida DV, Tyagi S, et al. Improving existing tools for Mycobacterium xenopi treatment: assessment of drug combinations and characterization of mouse models of infection and chemotherapy. J Antimicrob Chemother 2013; 68:659.</a></li><li><a class="nounderline abstract_t">Ferro BE, van Ingen J, Wattenberg M, et al. Time-kill kinetics of slowly growing mycobacteria common in pulmonary disease. J Antimicrob Chemother 2015; 70:2838.</a></li><li><a class="nounderline abstract_t">Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax 2017; 72:ii1.</a></li><li><a class="nounderline abstract_t">Lounis N, Truffot-Pernot C, Bentoucha A, et al. Efficacies of clarithromycin regimens against Mycobacterium xenopi in mice. Antimicrob Agents Chemother 2001; 45:3229.</a></li><li><a class="nounderline abstract_t">Klemens SP, Cynamon MH. Activities of azithromycin and clarithromycin against nontuberculous mycobacteria in beige mice. Antimicrob Agents Chemother 1994; 38:1455.</a></li></ol></div><div id="topicVersionRevision">Topic 107702 Version 10.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/369415" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Nontuberculous mycobacteria and associated diseases</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17277290" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23598956" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32628747" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13040295" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Human infection with atypical acid-fast organisms; report of two cases with pathologic findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1124888" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The course of untreated Mycobacterium kansasii disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3800137" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Sulfonamide-containing regimens for disease caused by rifampin-resistant Mycobacterium kansasii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7339801" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Treatment of pulmonary disease due to Mycobacterium kansasii: recent experience with rifampin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16537880" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12709349" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : In vitro activity of linezolid against slowly growing nontuberculous Mycobacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15824090" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15561826" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8075262" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Rifampin-resistant Mycobacterium kansasii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28461147" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Microbiological and Clinical Outcomes of Treating Non-Mycobacterium Avium Complex Nontuberculous Mycobacterial Pulmonary Disease: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14557961" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30827472" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Treatment with a macrolide-containing regimen for Mycobacterium kansasii pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12837729" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Activity of clarithromycin alone and in combination in a murine model of Mycobacterium kansasii infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12791475" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6650978" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8016763" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Research Committee, British Thoracic Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7780090" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Treatment of pulmonary disease caused by Mycobacterium kansasii: results of 18 vs 12 months' chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8994524" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pulmonary Mycobacterium kansasii infection: comparison of the clinical features, treatment and outcome with pulmonary tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19118226" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20499421" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clinical characteristics and treatment outcomes of Mycobacterium kansasii lung disease in Korea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12102303" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Pulmonary disease caused by Mycobacterium avium-intracellulare in HIV-negative patients: five-year follow-up of patients receiving standardised treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Mycobacterium malmoense sp. nov.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15527150" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Non-tuberculous mycobacteria: patterns of isolation. A multi-country retrospective survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8038315" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Infection with Mycobacterium malmoense in Sweden: report of 221 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19386689" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Clinical relevance of Mycobacterium malmoense isolation in The Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9770156" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Mycobacterium malmoense infections in the United States, January 1993 through June 1995.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9613641" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Susceptibilities of Mycobacterium malmoense determined at the growth optimum pH (pH 6.0).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12662005" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Pulmonary disease caused by M. malmoense in HIV negative patients: 5-yr follow-up of patients receiving standardised treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22763637" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22525524" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20006470" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : In vitro drug susceptibility of 2275 clinical non-tuberculous Mycobacterium isolates of 49 species in The Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Consensus management recommendations for additional nontuberculous mycobacterial pulmonary diseases</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18250184" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4955460" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Occurrence of atypical mycobacteria in Macacus rhesus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18444856" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Clinical relevance of Mycobacterium szulgai in The Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7582293" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Clinical isolates of Mycobacterium simiae in San Antonio, Texas. An 11-yr review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29760130" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Clinical, Radiological, and Microbiological Characteristics of Mycobacterium simiae Infection in 97 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32353074" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Mycobacterium simiae: Harmless colonizer or deadly pathogen?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18166593" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Clinical relevance of Mycobacterium simiae in pulmonary samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23027189" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22240424" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Pulmonary disease caused by Mycobacterium simiae in Iran's national referral center for tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23267789" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : First report of lung transplantation in a patient with active pulmonary Mycobacterium simiae infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9730300" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Successful treatment of disseminated Mycobacterium simiae infection in AIDS patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18619826" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Clinical and radiological features of Mycobacterium kansasii infection and Mycobacterium simiae infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6454654" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The effect of combined chemotherapy on suppressor T-cell activity in Mycobacterium simiae-infected mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7872769" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Activities of clarithromycin, ofloxacin, and clarithromycin plus ethambutol against Mycobacterium simiae in murine model of disseminated infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4673103" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Mycobacterium szulgai--a new pathogen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3579001" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The epidemiology of nontuberculous mycobacterial diseases in the United States. Results from a national survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24359518" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Clinical significance of Mycobacterium szulgai isolates from respiratory specimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22410245" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Long-term radiographic outcome of nodular bronchiectatic Mycobacterium avium complex pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14665782" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Pulmonary infection due to Mycobacterium szulgai.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9186149" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Mycobacterium szulgai infection of the lung: case report and review of an unusual pathogen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16946574" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Pulmonary nontuberculous mycobacterial infection caused by Mycobacterium szulgai in a young healthy woman.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13641655" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A strain of Mycobacterium isolated from skin lesions of a cold-blooded animal, Xenopus laevis, and its relation to atypical acid-fast bacilli occurring in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17138678" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Respiratory infections associated with nontuberculous mycobacteria in non-HIV patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19793424" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Pulmonary Mycobacterium xenopi infection in non-HIV-infected patients: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18325251" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Mycobacterium xenopi clinical relevance and determinants, the Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19052044" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Mycobacterium xenopi pulmonary infections: a multicentric retrospective study of 136 cases in north-east France.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15472795" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A decade surveillance study of Mycobacterium xenopi disease and antimicrobial susceptibility levels in a reference teaching hospital of northern Italy: HIV-associated versus non-HIV-associated infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23129730" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Improving existing tools for Mycobacterium xenopi treatment: assessment of drug combinations and characterization of mouse models of infection and chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26142475" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Time-kill kinetics of slowly growing mycobacteria common in pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29054853" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11600387" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Efficacies of clarithromycin regimens against Mycobacterium xenopi in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7979271" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Activities of azithromycin and clarithromycin against nontuberculous mycobacteria in beige mice.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
